Cargando…
Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels
COVID-19 is characterized by persistent symptoms beyond acute illness. In this prospective cohort study of patients with COVID-19, we sought to characterize the prevalence and persistence of symptoms up to 18 months after diagnosis. We followed 166 patients and assessed their symptoms during acute i...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784691/ https://www.ncbi.nlm.nih.gov/pubmed/36556030 http://dx.doi.org/10.3390/jcm11247413 |
_version_ | 1784857869514964992 |
---|---|
author | Kalak, George Jarjou’i, Amir Bohadana, Abraham Wild, Pascal Rokach, Ariel Amiad, Noa Abdelrahman, Nader Arish, Nissim Chen-Shuali, Chen Izbicki, Gabriel |
author_facet | Kalak, George Jarjou’i, Amir Bohadana, Abraham Wild, Pascal Rokach, Ariel Amiad, Noa Abdelrahman, Nader Arish, Nissim Chen-Shuali, Chen Izbicki, Gabriel |
author_sort | Kalak, George |
collection | PubMed |
description | COVID-19 is characterized by persistent symptoms beyond acute illness. In this prospective cohort study of patients with COVID-19, we sought to characterize the prevalence and persistence of symptoms up to 18 months after diagnosis. We followed 166 patients and assessed their symptoms during acute illness, and at 3 and 18 months after disease onset. The mean number of symptoms per patient during acute disease was 2.3 (SD:1.2), dropping to 1.8 (SD:1.1) at 3 months after recovery and to 0.6 (SD:0.9) at 18 months after recovery. However, this decrease was not unidirectional. Between acute illness and 3 months, the frequency of symptoms decreased for cough (64.5%→24.7%), ageusia (21.7% to6%), anosmia (17.5%→5.4%), and generalized pain (10.8% to 5.4%) but increased for dyspnea (53%→57.2%) weakness (47%→54.8%), and brain fog (3%→8.4%). Between 3 and 18 months, the frequency of symptoms decreased for all symptoms but remained relatively high for dyspnea (15.8%), weakness (21.2%), and brain fog (7.3%). Symptoms may persist for at least 18 months after acute COVID-19 infection. During the medium- to long-term recovery period, the prevalence of some symptoms may decrease or remain stable, and the prevalence of others may increase before slowly decreasing thereafter. These data should be considered when planning post-acute care for these patients. |
format | Online Article Text |
id | pubmed-9784691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97846912022-12-24 Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels Kalak, George Jarjou’i, Amir Bohadana, Abraham Wild, Pascal Rokach, Ariel Amiad, Noa Abdelrahman, Nader Arish, Nissim Chen-Shuali, Chen Izbicki, Gabriel J Clin Med Article COVID-19 is characterized by persistent symptoms beyond acute illness. In this prospective cohort study of patients with COVID-19, we sought to characterize the prevalence and persistence of symptoms up to 18 months after diagnosis. We followed 166 patients and assessed their symptoms during acute illness, and at 3 and 18 months after disease onset. The mean number of symptoms per patient during acute disease was 2.3 (SD:1.2), dropping to 1.8 (SD:1.1) at 3 months after recovery and to 0.6 (SD:0.9) at 18 months after recovery. However, this decrease was not unidirectional. Between acute illness and 3 months, the frequency of symptoms decreased for cough (64.5%→24.7%), ageusia (21.7% to6%), anosmia (17.5%→5.4%), and generalized pain (10.8% to 5.4%) but increased for dyspnea (53%→57.2%) weakness (47%→54.8%), and brain fog (3%→8.4%). Between 3 and 18 months, the frequency of symptoms decreased for all symptoms but remained relatively high for dyspnea (15.8%), weakness (21.2%), and brain fog (7.3%). Symptoms may persist for at least 18 months after acute COVID-19 infection. During the medium- to long-term recovery period, the prevalence of some symptoms may decrease or remain stable, and the prevalence of others may increase before slowly decreasing thereafter. These data should be considered when planning post-acute care for these patients. MDPI 2022-12-14 /pmc/articles/PMC9784691/ /pubmed/36556030 http://dx.doi.org/10.3390/jcm11247413 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Kalak, George Jarjou’i, Amir Bohadana, Abraham Wild, Pascal Rokach, Ariel Amiad, Noa Abdelrahman, Nader Arish, Nissim Chen-Shuali, Chen Izbicki, Gabriel Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels |
title | Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels |
title_full | Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels |
title_fullStr | Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels |
title_full_unstemmed | Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels |
title_short | Prevalence and Persistence of Symptoms in Adult COVID-19 Survivors 3 and 18 Months after Discharge from Hospital or Corona Hotels |
title_sort | prevalence and persistence of symptoms in adult covid-19 survivors 3 and 18 months after discharge from hospital or corona hotels |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784691/ https://www.ncbi.nlm.nih.gov/pubmed/36556030 http://dx.doi.org/10.3390/jcm11247413 |
work_keys_str_mv | AT kalakgeorge prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT jarjouiamir prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT bohadanaabraham prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT wildpascal prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT rokachariel prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT amiadnoa prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT abdelrahmannader prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT arishnissim prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT chenshualichen prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels AT izbickigabriel prevalenceandpersistenceofsymptomsinadultcovid19survivors3and18monthsafterdischargefromhospitalorcoronahotels |